Relevant Publications

Bedimo R, Chen R, Accort N, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989 to 2002. Clin Infect Dis. 2004 Nov 1;39(9):1380-4.

Bedimo R, Hoesley C, Saag M. Non-AIDS-defining malignancies in the HAART era. Reply to Dal Maso et al. Clin Infect Dis. 2005 Jul 1;41(1):126-127.

Bedimo R, Chen R, Westfall A, Raper J, Allison J and Saag, M. Sustained HIV viral suppression following treatment interruption: an observational study. AIDS Research and Human Retroviruses. 2006 Jan;22(1):40-4.

Bedimo R, Ghurani R, Nsuami M, Turner D, Kvanli M, Brown G, and Margolis D. Lipid abnormalities in HIV/HCV co-infected patients. HIV Medicine, 2006 Nov;7(8):530-6.

Kaur R, Bedimo R, Kvanli M, Turner D, Shaw L, and Margolis D. A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil. AIDS Research and Therapy 2006 May 26;3(1):16.

Busti AJ, Bedimo R, Margolis D, Hardin D. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated patients after switch to atazanavir/ritonavir (ATV/RTV): A prospective study using hyperinsulinemic, euglycemic clamp testing. Antiv Ther 2006;11:L37.

Chastain LM, Bain AM, Edwards KL, Bedimo R, Busti AJ. A retrospective study of the lipid lowering efficacy and safety of
ezetimibe added to HMG-CoA reductase therapy in HIV-infected patients with hyperlipidemia. Journal of Clinical Lipidology. 2007;1: 634-639

Nguyen ST, Eaton SA, Bain A, Payne K, Rahman A, Bedimo R, Herrington J, Maclayton D, Rodriguez-Barradas M, Busti AJ. The lipid lowering efficacy and safety after a switch to an atazanavir/ritonavir based HAART in HIV-infected patients: a multi-center retrospective study. Pharmacotherapy. 2008 Mar;28(3):323-30.

Rahman AP, Eaton SA, Nguyen, S, Bain AM, Payne K, Bedimo R., and Busti AJ. The safety and efficacy of simvastatin in treating
hyperlipidemia in HIV-infected patients on efavirenz-based HAART. Pharmacotherapy 2008;28(3):323-330

Bain AM, Payne KD, Rahman AP, Bedimo R, McClayton D, Rodriguez-Barradas M, and Busti AJ. The lipid-lowering efficacy of
switching within non-nucleoside reverse transcriptase inhibitors in HIV-infected patients. American Journal of Infectious Diseases 2008;4 (2): 147-151

Busti AJ, Bedimo R, Margolis DM, Hardin DS. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir. J Investig Med. 2008 Feb;56(2):539-44

Busti AJ, Bain AM, Hall RG 2nd, Bedimo RJ, Leff RD, Meek C, Mehvar R. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol. 2008 Jun;51(6):605-10.

Bedimo, RJ. Body-fat abnormalities in patients with HIV: Progress and challenges. Journal of the International Association of
Physicians in AIDS Care (JIAPAC)
2008 Nov-Dec;7(6):292-305.

Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of non-AIDS-defining malignancies in HIV-infected vs. non-infected veterans in the HAART era: Impact of immunosuppression. Journal of Acquired Immune Deficiency Syndromes. 2009;52:203-208.

Bedimo R, Westfall AO, Mugavero M, Drechsler H, Khanna N, Saag M. Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010,11:462-468.